

Premenstrual Syndrome Treatment Market Trends, Size, Growth & Forecast 2028

The Global Premenstrual Syndrome Treatment Market is expected to grow at a high CAGR of 4% during the forecasting period (2021-2028).

CLEVELAND, OHIO, UNITED STATE AMERICA, September 24, 2021 /EINPresswire.com/ --

Market Overview

Premenstrual Syndrome is an aggregate of physical and emotional symptoms, which includes mood swings, frame aches, fatigue, tender breasts, food cravings, fatigue, irritability, and melancholy. It arises around the end of the luteal segment and dissipates with menstruation or shortly thereafter. It is maximum normally discovered among ladies with an excessive level of stress, despair, cyclic modifications inside the menstruation cycle, and chemical changes inside the brain. Approximately 3 out of 4 ladies revel in have reveled in any shape experienced some form of premenstrual syndrome.



The Global Premenstrual Syndrome Treatment Market is expected to grow at a high CAGR of 4% during the forecasting period (2021-2028)."

DataM Intelligence

View full report:

<https://www.datamintelligence.com/research-report/premenstrual-syndrome-treatment-market>

Market Dynamics:

The larger centered populace drives the marketplace as it

is the maximum common fitness problem in girls of reproductive age. According to Petranka Chumpalova et al. 2020, in a study published within the Annals of General Psychiatry magazine, 90% of women of reproductive age experience several premenstrual symptoms that vary from mild to intense. Approximately 20-40% of these girls be afflicted by Premenstrual Syndrome, and around 2-8% of these ladies suffer from the premenstrual dysphoric disease (PMDD) worldwide.

The undergoing research and improvement activities to increase treatments for Premenstrual



Syndrome shall positively impact the market. For instance, the scientific research demonstrated that the management of the PH80-PMD (Pherin Pharmaceuticals) administered intranasally PRN reduced moderate and excessive premenstrual signs and symptoms significantly higher as compared to the placebo at some point of the critical premenstrual days of the cycle without the want for continual administration.

Asarina Pharma is developing an ability remedy for the treatment of Premenstrual Dysphoric Disorder (PMDD), an extreme and disabling shape of premenstrual syndrome. Its lead product, i.E., Sepranolone, had met its primary safety and efficacy endpoints in a new Phase IIa observe involving 120 ladies with Premenstrual Dysphoric Disorder. Sepranolone is a proprietary, first-in-elegance, endogenous, small molecule that acts as a GABA-A modulating steroid antagonist (GAMSA).

There is an increase in cognizance concerning the diagnosis, remedy, and reimbursement of Premenstrual Syndrome worldwide. For example, in June 2019, Premenstrual dysphoric ailment (PMDD) has been given its very own class code and, for the primary time, categorized without a doubt as a gynecological, now not intellectual, ailment in the WHO's new International Classification of Diseases, ICD-11. The inclusion of PMDD in ICD-eleven is an important indicator of the growing scientific attention of PMDD international and a growing medical consensus that PMDD is a hormonal, now not psychiatric situation. PMDD is stated within the WHO's present ICD-10, but not directly as a sub-class below 'Premenstrual tension syndrome.

However, the facet-results associated with the use of treatment options for Premenstrual Syndrome shall hider market increase. For instance, using selective serotonin reuptake inhibitors (SSRIs) outcomes in unfavorable events such as nausea, asthenia, fatigue, sexual dysfunction, and reduced energy. Gonadotropin-releasing hormones (GnRH) analogs are not encouraged for a long time as these analogs lead to negative consequences on bone density and boom the chance of developing bone thinning.

Segment Analysis

By Drug Class

- Analgesics
- Antidepressants
- Oral Contraceptives
- Ovarian Suppression Agents
- Gonadotropin-releasing hormone (GnRH) Analogues
- Estrogen-only patches & implants
- Selective serotonin reuptake inhibitors (SSRIs)
- Others

By Distribution Channel

- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers

•Others

Download free sample: <https://www.datamintelligence.com/download-sample/premenstrual-syndrome-treatment-market>

Geographical Presentation

By region, the Premenstrual Syndrome treatment marketplace is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the areas, North America ruled the Premenstrual Syndrome Treatment Market because of the growing incidence of Premenstrual Syndrome. According to the American Academy of Family Physicians, approximately ninety% of childbearing age ladies enjoy premenstrual signs and symptoms, and much less than 10% are identified with premenstrual dysphoric sickness (PMDD). The growing consciousness concerning women's health shall stimulate market increase. For example, The Office on Women's Health (OWH) in the U.S. Department of Health and Human Services (HHS) is involved in growing attention via addressing the critical women's health troubles. It allows information and boost policies, educates experts and purchasers, and helps programs related to women's fitness, together with the Premenstrual Syndrome.

The Asia-Pacific is expected to have a fantastic market increase because of many females of childbearing age. There are growing authorities projects and campaigns for enhancing girls' and maternity health. For instance, India's National Health Portal creates recognition of women's health issues, which includes Premenstrual Syndrome. The rising expenditure for enhancing the healthcare facilities and infrastructure shall have a fantastic impact on the market. A substantial marketplace boom is anticipated to be found in developing international locations, consisting of India & China.

Competitive Analysis

Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer Inc., H. Lundbeck A/S are the leading market players with significant market share. The new product development, opportunity, and revenue generation shall intensify the market competition.

The companies use strategies such as collaborations, mergers, strategic partnerships, and acquisitions to hold their positions in the market. For instance, in November 2016, Ergomed plc had entered into the co-development agreement with Asarina Pharma AB (Asarina) for the Phase IIb clinical development of Sepranolone (UC1010) as a targeted treatment for patients with the premenstrual dysphoric disorder (PMDD). Under the terms of the agreement, Ergomed would be responsible for the clinical development organization contracted to conduct Asarina's multicentre, multinational, randomized Phase IIb clinical trial.

In March 2011, Sanofi-aventis had acquired Chattem, Inc. Under the terms of the agreement, Chattem, Inc would be a wholly-owned subsidiary of the Sanofi-aventis Group.

The companies are raising investment and funding for the development of therapies for the

treatment of Premenstrual Syndrome. For instance, in November 2016, Asarina Pharma had completed a financing round raising EURO 7 million from new and existing investors for the continued clinical development of Sepranolone.

Related Topic's

[Varicose Veins Treatment Market](#), [Non-Opioid Pain Treatment Market](#), [Amyloidosis Treatment Market](#)

Sai Kiran

DataM Intelligence 4Market Research LLP

+1 8774414866

sai.k@datamintelligence.com

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552230226>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.